![Mark Heffernan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Heffernan
Amministratore Delegato presso Stonehaven Incubate AG
Posizioni attive di Mark Heffernan
Società | Posizione | Inizio | Fine |
---|---|---|---|
Stonehaven Incubate AG
![]() Stonehaven Incubate AG Financial ConglomeratesFinance Stonehaven Incubate AG provides investment services in animal health sector. The company is headquartered in Andermatt, Switzerland. | Amministratore Delegato | - | - |
AniV8, Inc.
![]() AniV8, Inc. Miscellaneous Commercial ServicesCommercial Services AniV8, Inc. is an American clinical sensor technology company that aims to improve animal health by applying innovative, high-tech sensor science to targeted disease states. AniV8 has developed the first wearable health monitor for dogs and cats that will diagnose and monitor osteoarthritis (OA) pain using proprietary algorithms to measure the quality of movement. The device has clear points of difference from competitors and is the only wearable to measure the quality, not quantity, of motion. AniV8 has completed an oversubscribed pre-seed funding round and has collaborated with Elanco Animal Health to evaluate its wearable technology in research settings. The company was founded by B Duncan X. Lascelles, who is also the director and chief scientific advisor, and the CEO is Ellie Virtue. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Mark Heffernan
Precedenti posizioni note di Mark Heffernan
Società | Posizione | Inizio | Fine |
---|---|---|---|
NEXVET BIOPHARMA PUBLIC LIMITED CO | Direttore/Membro del Consiglio | 01/04/2011 | 31/07/2017 |
Amministratore Delegato | 01/04/2011 | 31/07/2017 | |
Fondatore | 01/04/2011 | 31/07/2017 | |
Nexvet Australia Pty Ltd.
![]() Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Direttore/Membro del Consiglio | 01/02/2010 | 01/07/2017 |
Amministratore Delegato | 01/02/2010 | 01/07/2017 | |
Fondatore | 01/02/2010 | 01/07/2017 | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Direttore/Membro del Consiglio | 06/05/2011 | 06/05/2011 |
Amministratore Delegato | 01/01/2003 | 01/12/2011 | |
Fondatore | 06/05/2011 | 06/05/2011 | |
Scout Bio, Inc.
![]() Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Amministratore Delegato | - | - |
PERCHERON THERAPEUTICS LIMITED | Corporate Officer/Principal | - | - |
Formazione di Mark Heffernan
Monash University | Doctorate Degree |
Statistiche
Distribuzione geografica
Australia | 4 |
Irlanda | 3 |
Stati Uniti | 3 |
Posizioni
Chief Executive Officer | 5 |
Director/Board Member | 4 |
Founder | 3 |
Settori
Health Technology | 6 |
Consumer Services | 2 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
PERCHERON THERAPEUTICS LIMITED | Health Technology |
Aziende private | 6 |
---|---|
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Nexvet Australia Pty Ltd.
![]() Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Nexvet Biopharma Plc
![]() Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
Scout Bio, Inc.
![]() Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
Stonehaven Incubate AG
![]() Stonehaven Incubate AG Financial ConglomeratesFinance Stonehaven Incubate AG provides investment services in animal health sector. The company is headquartered in Andermatt, Switzerland. | Finance |
AniV8, Inc.
![]() AniV8, Inc. Miscellaneous Commercial ServicesCommercial Services AniV8, Inc. is an American clinical sensor technology company that aims to improve animal health by applying innovative, high-tech sensor science to targeted disease states. AniV8 has developed the first wearable health monitor for dogs and cats that will diagnose and monitor osteoarthritis (OA) pain using proprietary algorithms to measure the quality of movement. The device has clear points of difference from competitors and is the only wearable to measure the quality, not quantity, of motion. AniV8 has completed an oversubscribed pre-seed funding round and has collaborated with Elanco Animal Health to evaluate its wearable technology in research settings. The company was founded by B Duncan X. Lascelles, who is also the director and chief scientific advisor, and the CEO is Ellie Virtue. | Commercial Services |
- Borsa valori
- Insiders
- Mark Heffernan
- Esperienza